These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 34036837)
1. Review of Prothrombin Complex Concentrates Use in Apixaban and Rivaroxaban Associated Intracranial Hemorrhages. Ibarra F J Pharm Pract; 2022 Dec; 35(6):1012-1020. PubMed ID: 34036837 [TBL] [Abstract][Full Text] [Related]
2. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis. Costa OS; Connolly SJ; Sharma M; Beyer-Westendorf J; Christoph MJ; Lovelace B; Coleman CI Crit Care; 2022 Jun; 26(1):180. PubMed ID: 35710578 [TBL] [Abstract][Full Text] [Related]
3. Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products. Castillo R; Chan A; Atallah S; Derry K; Baje M; Zimmermann LL; Martin R; Groysman L; Stern-Nezer S; Minokadeh A; Nova A; Huang W; Cang W; Schomer K J Thromb Thrombolysis; 2021 Jan; 51(1):151-158. PubMed ID: 32500220 [TBL] [Abstract][Full Text] [Related]
4. Comparison of 4-factor prothrombin complex concentrate and andexanet alfa for reversal of apixaban and rivaroxaban in the setting of intracranial hemorrhage. Lipski M; Pasciolla S; Wojcik K; Jankowitz B; Igneri LA J Thromb Thrombolysis; 2023 Apr; 55(3):519-526. PubMed ID: 36566473 [TBL] [Abstract][Full Text] [Related]
5. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhages. Pham H; Medford WG; Horst S; Levesque M; Ragoonanan D; Price C; Colbassani H; Piper K; Chastain K Am J Emerg Med; 2022 May; 55():38-44. PubMed ID: 35272069 [TBL] [Abstract][Full Text] [Related]
6. Factor Xa Inhibitor-Related Intracranial Hemorrhage: Results From a Multicenter, Observational Cohort Receiving Prothrombin Complex Concentrates. Panos NG; Cook AM; John S; Jones GM; Circulation; 2020 May; 141(21):1681-1689. PubMed ID: 32264698 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of andexanet alfa and four-factor prothrombin complex concentrate (4F-PCC) for reversal of rivaroxaban- and apixaban-associated intracranial hemorrhages. Barra ME; Das AS; Hayes BD; Rosenthal ES; Rosovsky RP; Fuh L; Patel AB; Goldstein JN; Roberts RJ J Thromb Haemost; 2020 Jul; 18(7):1637-1647. PubMed ID: 32291874 [TBL] [Abstract][Full Text] [Related]
8. Administration of 4-Factor Prothrombin Complex Concentrate as an Antidote for Intracranial Bleeding in Patients Taking Direct Factor Xa Inhibitors. Grandhi R; Newman WC; Zhang X; Harrison G; Moran C; Okonkwo DO; Ducruet AF World Neurosurg; 2015 Dec; 84(6):1956-61. PubMed ID: 26341438 [TBL] [Abstract][Full Text] [Related]
9. The use of andexanet alfa and 4-factor prothrombin complex concentrate in intracranial hemorrhage. Oh ES; Schulze P; Diaz F; Shah K; Rios J; Silverman ME Am J Emerg Med; 2023 Feb; 64():74-77. PubMed ID: 36463661 [TBL] [Abstract][Full Text] [Related]
10. Impact of Factor Xa Inhibitor Reversal with Prothrombin Complex Concentrate in Patients with Traumatic Brain Injuries. Cooksey GE; Hamilton LA; McMillen JC; Griffard JH; Rowe AS Neurocrit Care; 2022 Oct; 37(2):471-478. PubMed ID: 35624388 [TBL] [Abstract][Full Text] [Related]
11. Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage. Vestal ML; Hodulik K; Mando-Vandrick J; James ML; Ortel TL; Fuller M; Notini M; Friedland M; Welsby IJ J Thromb Thrombolysis; 2022 Jan; 53(1):167-175. PubMed ID: 34101050 [TBL] [Abstract][Full Text] [Related]
12. Emergent reversal of oral factor Xa inhibitors with four-factor prothrombin complex concentrate. Lipari L; Yang S; Milligan B; Blunck J Am J Emerg Med; 2020 Dec; 38(12):2641-2645. PubMed ID: 33041150 [TBL] [Abstract][Full Text] [Related]
13. Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study. Smith MN; Deloney L; Carter C; Weant KA; Eriksson EA J Thromb Thrombolysis; 2019 Aug; 48(2):250-255. PubMed ID: 30941571 [TBL] [Abstract][Full Text] [Related]
14. Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study. Schulman S; Gross PL; Ritchie B; Nahirniak S; Lin Y; Lieberman L; Carrier M; Crowther MA; Ghosh I; Lazo-Langner A; Zondag M; Thromb Haemost; 2018 May; 118(5):842-851. PubMed ID: 29564837 [TBL] [Abstract][Full Text] [Related]
15. Andexanet alfa effectiveness and safety versus four-factor prothrombin complex concentrate (4F-PCC) in intracranial hemorrhage while on apixaban or rivaroxaban: A single-center, retrospective, matched cohort analysis. Parsels KA; Seabury RW; Zyck S; Miller CD; Krishnamurthy S; Darko W; Probst LA; Latorre JG; Cwikla GM; Feldman EA Am J Emerg Med; 2022 May; 55():16-19. PubMed ID: 35245776 [TBL] [Abstract][Full Text] [Related]
16. Comparison of 4-factor PCC reversal of apixaban and rivaroxaban versus warfarin for intracranial hemorrhage. Pasciolla S; Wojcik K; Kavi T; Green D; Shaikh H; Jankowitz B; Igneri LA J Thromb Thrombolysis; 2022 Jul; 54(1):74-81. PubMed ID: 34837144 [TBL] [Abstract][Full Text] [Related]
17. Reversal of Apixaban and Rivaroxaban Using Activated Prothrombin Complex Concentrates in Patients with Major Bleeding. Sheikh-Taha M; Crawley RM Am J Cardiovasc Drugs; 2020 Jun; 20(3):295-299. PubMed ID: 31709499 [TBL] [Abstract][Full Text] [Related]
18. Four-factor prothrombin complex concentrate for life-threatening bleeds or emergent surgery: A retrospective evaluation. Sin JH; Berger K; Lesch CA J Crit Care; 2016 Dec; 36():166-172. PubMed ID: 27546767 [TBL] [Abstract][Full Text] [Related]
19. Factor VIII Inhibitor Bypassing Activity (FEIBA) Reversal for Apixaban and Rivaroxaban in Patients With Acute Intracranial and Nonintracranial Hemorrhage. Hunt AR; Coffeen SN; Shiltz DL; Ice C; Parker J Ann Pharmacother; 2021 Dec; 55(12):1455-1466. PubMed ID: 33843267 [TBL] [Abstract][Full Text] [Related]
20. Prothrombin complex concentrates for the urgent reversal of apixaban and rivaroxaban: an Australian retrospective cohort study. Wallwork S; Wang Y; Chaiwatanatorn K; Cole-Sinclair M Intern Med J; 2023 May; 53(5):803-811. PubMed ID: 34779569 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]